(Total Views: 840)
Posted On: 01/19/2022 3:46:30 PM
Post# of 148870
It looks like Merck's new Neuro partner, Yumanity Therapeutics, is running into a snag in their multi-dose portion of their Parkinson's trial.
https://finance.yahoo.com/news/yumanity-repor...00297.html
https://finance.yahoo.com/news/yumanity-repor...00297.html
(0)
(0)Scroll down for more posts ▼
